Ad is loading...
CVLFX
Price
$14.60
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VVIAX
Price
$69.72
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

CVLFX vs VVIAX

Header iconCVLFX vs VVIAX Comparison
Open Charts CVLFX vs VVIAXBanner chart's image
Cullen Value C
Price$14.60
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
CVLFX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVLFX vs. VVIAX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVLFX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. CVLFX (24.2M). VVIAX pays higher dividends than CVLFX: VVIAX (2.36) vs CVLFX (0.70). CVLFX was incepted earlier than VVIAX: CVLFX (12 years) vs VVIAX (24 years). CVLFX is a more actively managed with annual turnover of: 27.00 vs. VVIAX (10.00). CVLFX has a lower initial minimum investment than VVIAX: CVLFX (1000) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. CVLFX (12.32). VVIAX return over 5 years is better than : 53.09 vs. CVLFX (-11.61).
CVLFXVVIAXCVLFX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years24 years-
Gain YTD14.33819.67273%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets24.2M184B0%
Annual Yield % from dividends0.702.3630%
Returns for 1 year12.3226.0947%
Returns for 3 years-9.4624.77-38%
Returns for 5 years-11.6153.09-22%
Returns for 10 years14.83112.2613%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics